Global CRISPR and Cas Gene Market

Global CRISPR and Cas Gene Market Size, Share, Growth Analysis, By Product Type(Crispr enzymes, crispr kits), By Application(Biomedical research, therapeutics), By End-user(Academic and research institutes, pharmaceutical and biotechnology companies) - Industry Forecast 2024-2031

Report ID: SQMIG35H2170 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 91 | Figures: 76

Global CRISPR and Cas Gene Market News

  • In April 2023, Vertex and Crispr Therapeutics submitted their CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) for FDA approval, for sickle cell disease (SCD) and beta-thalassemia.
  • Ensoma purchased Twelve Bio ApS in February 2023 in order to expand the range of in vivo designed cell treatments that it offers. Twelve Bio is a startup that investigates the potential therapeutic uses of next-generation CRISPR-Cas medications.
  • In December 2022, a clinical trial was sponsored by the University of California, San Francisco (UCSF) and is being conducted by Dr. Mark Walters. The trial is testing the safety and efficacy of CRISPR_SCD001, a gene-editing therapy for sickle cell disease. CRISPR_SCD001 uses the CRISPR/Cas9 gene-editing tool to correct a genetic mutation in the blood stem cells of patients with severe SCD.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global CRISPR And Cas Gene Market size was valued at USD 2.56 billion in 2022 and is poised to grow from USD 3.50 billion in 2023 to USD 42.67 billion by 2031, at a CAGR of 36.70% during the forecast period (2024-2031).

The CRISPR and Cas genes market is highly competitive, with several key players leading the industry. These companies are actively engaged in research and development to improve the efficiency and specificity of CRISPR-based gene-editing tools. Collaboration and strategic partnerships between biotechnology companies, academic institutions, and research organizations are common in the market, fostering innovation and driving market growth. 'CRISPR Therapeutics AG (Switzerland)', 'Editas Medicine, Inc. (US)', 'Intellia Therapeutics, Inc. (US)', 'Caribou Biosciences, Inc. (US)', 'CRISPR/Cas9 Therapeutics (US)', 'Synthego Corporation (US)', 'Horizon Discovery Group plc (UK)', 'Mammoth Biosciences, Inc. (US)', 'Precision Biosciences, Inc. (US)', 'Beam Therapeutics Inc. (US)', 'Sangamo Therapeutics, Inc. (US)', 'Cellectis S.A. (France)', 'GenScript Biotech Corporation (China)', 'Agilent Technologies, Inc. (US)', 'Lonza Group Ltd. (Switzerland)', 'Thermo Fisher Scientific, Inc. (US)', 'Merck KGaA (Germany)', 'Qiagen N.V. (Netherlands)', 'New England Biolabs, Inc. (US)', 'Addgene (US)'

Genetic disorders encompass a wide range of conditions caused by mutations or alterations in specific genes. As the understanding of the genetic basis of diseases improves, the demand for precise and efficient gene-editing technologies like crispr and cas genes increases. These technologies hold immense potential for developing targeted therapies and personalized treatments for genetic disorders. The rising global burden of genetic diseases, coupled with the need for effective treatment options, drives the demand for crispr and cas genes, thereby propelling market growth.

Increasing adoption of crispr technology in agriculture and food production: The agricultural sector is embracing crispr gene editing as a powerful tool to enhance crop traits, improve disease resistance, and develop genetically modified organisms (gmos). Crispr enables precise and targeted modifications in plant genomes, allowing breeders to accelerate the development of desirable traits, such as increased yield, drought tolerance, and nutritional value. This trend aligns with the growing global demand for sustainable agriculture, improved crop productivity, and the need to address food security challenges.

The largest market region in the crispr and cas genes market is North america. North America dominates the market due to several factors that contribute to its significant market share. The region is home to major biotechnology companies, renowned academic and research institutions, and a robust research infrastructure. These factors facilitate extensive research and development activities related to crispr and cas genes, driving the market's growth. Additionally, North America benefits from supportive regulatory frameworks that promote innovation and the commercialization of gene-editing technologies. The region's strong presence in the market is further reinforced by the high investments in biotechnology and genetic research, as well as the increasing adoption of crispr-based tools and therapies in healthcare applications.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Global Oxidative Stress Assay Market
Buy Now GET FREE SAMPLE
Global Scaffold Technology Market
Buy Now GET FREE SAMPLE
Global Procedure Trays Market
Buy Now GET FREE SAMPLE
Gout Therapeutics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global CRISPR and Cas Gene Market

Product ID: SQMIG35H2170

$5,300
BUY NOW GET FREE SAMPLE